About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Study: 2 Radiotherapy Treatments Show Similar Morbidity, Cancer Control After Prostatectomy

by Rukmani Krishna on May 23, 2013 at 12:04 AM
Font : A-A+

 Study: 2 Radiotherapy Treatments Show Similar Morbidity, Cancer Control After Prostatectomy

According to a study, use of the newer, more expensive intensity-modulated radiotherapy (IMRT) and use of the older conformal radiotherapy (CRT) after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes. The study was published Online First by JAMA Internal Medicine, a JAMA Network publication.

Gregg H. Goldin, M.D., of the University of North Carolina at Chapel Hill, and colleagues analyzed data from the Surveillance, Epidemiology and End Results-Medicare-linked database to identify patients who received IMRT or CRT. The study included the outcomes of 457 IMRT and 557 CRT patients who received radiotherapy between 2002 and 2007.

Advertisement

The use of IMRT increased from zero in 2000 to 82.1 percent in 2009. Men who received IMRT vs. CRT showed no significant difference in rates of long-term gastrointestinal morbidity, urinary nonincontinent morbidity, urinary incontinence or erectile dysfunction. There also appeared to be no difference in subsequent treatment for recurrent disease, according to the study results.

"Our results provide new and important information to patients, physicians, and other decision makers on the currently available evidence regarding the outcomes of different postprostatectomy radiation techniques. The potential clinical benefit of IMRT compared with CRT in this setting is unclear," the study concludes.(JAMA Intern Med. Published online May 20, 2013.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

Combination Therapy may Benefit Leukemia Patients
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
 Myelofibrosis: New Drugs to Revolutionize Treatment
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
 Blood Vessels Can Kill Cancer Cells and Stop Breast Cancer Spread
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
 Weed Killer Agent Orange May Increase the Risk of Blood Cancer Among Veterans
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Two Years: Optimal Duration of Immunotherapy in Advanced Lung Cancer
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Study: 2 Radiotherapy Treatments Show Similar Morbidity, Cancer Control After Prostatectomy Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests